DeepMed Research

GeneOne Life Science, Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1976-01-01

Employees: -

Market Cap: -

Website: http://www.genels.com

Clinical Trials

GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)

Phase 1

Active, not recruiting

Conditions: Healthy
COVID-19

Interventions: Drug: GLS-5310 (Group 3)
Drug: GLS-5310 (Group 2)
Drug: GLS-5310 (Group 4)
Drug: GLS-5310 (Group 1)

First Posted Date: 2022-01-10

Last Posted Date: 2023-09-13

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 69

Registration Number: NCT05182567

Locations: 🇺🇸
Meridian Clinical Research, Lincoln, Nebraska, United States
🇵🇷
Clinical Research Puerto Rico, San Juan, Puerto Rico

GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)

Phase 1

Conditions: Healthy
Covid19

Interventions: Biological: GLS-5130
Biological: Placebo

First Posted Date: 2021-10-20

Last Posted Date: 2021-10-20

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 30

Registration Number: NCT05085639

Locations: 🇵🇷
University of Puerto Rico, San Juan, Puerto Rico
🇵🇷
Clinical Research Puerto Rico, San Juan, Puerto Rico

GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)

Phase 1

Completed

Conditions: SARS-CoV-2

Interventions: Biological: GLS-5310
Biological: Placebo

First Posted Date: 2020-12-17

Last Posted Date: 2024-11-27

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 183

Registration Number: NCT04673149

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

Phase 2

Completed

Conditions: Pneumonitis
SARS-CoV Infection

Interventions: Drug: GLS-1027
Drug: Placebo

First Posted Date: 2020-10-19

Last Posted Date: 2025-04-11

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 132

Registration Number: NCT04590547

Locations: 🇧🇬
MHAT Kozlodui, Kozloduy, Bulgaria
🇧🇬
SHATPPD d-r Dimitar Gramatikov, Department of Pneumology, Ruse, Bulgaria
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

and more 14 locations

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Phase 2

Terminated

Conditions: SARS-CoV 2
Infection

Interventions: Drug: GLS-1200
Drug: Placebo

First Posted Date: 2020-05-29

Last Posted Date: 2023-02-21

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 184

Registration Number: NCT04408183

Locations: 🇺🇸
Sinus and Nasal Specialists of Louisiana, Baton Rouge, Louisiana, United States
🇺🇸
Conroe Willis Medical Reasearch, Conroe, Texas, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery

Phase 2

Not yet recruiting

Conditions: Sinusitis Chronic

Interventions: Drug: GLS-1200
Drug: Placebo

First Posted Date: 2019-08-19

Last Posted Date: 2023-01-11

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 99

Registration Number: NCT04060316

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: GLS-5300
Device: Cellectra 2000 Electroporation

First Posted Date: 2018-10-26

Last Posted Date: 2020-05-27

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 60

Registration Number: NCT03721718

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of

Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection

Phase 1

Completed

Conditions: HCV Infection

Interventions: Biological: GLS-6150

First Posted Date: 2018-09-17

Last Posted Date: 2020-05-27

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 32

Registration Number: NCT03674125

Locations: 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

GLS-5700 in Dengue Virus Seropositive Adults

Phase 1

Completed

Conditions: Zika
Healthy

Interventions: Biological: Placebo
Biological: GLS-5700

First Posted Date: 2016-09-02

Last Posted Date: 2022-01-20

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 160

Registration Number: NCT02887482

Locations: 🇵🇷
Clinical Research of Puerto Rico, San Juan, Puerto Rico
🇵🇷
University of Puerto Rico, San Juan, Puerto Rico
🇵🇷
Fundacion De Investigation, San Juan, Puerto Rico

GLS-5700 in Dengue Virus-Naïve Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: GLS-5700

First Posted Date: 2016-06-22

Last Posted Date: 2024-12-24

Lead Sponsor: GeneOne Life Science, Inc.

Target Recruit Count: 40

Registration Number: NCT02809443

Locations: 🇺🇸
Miami Research Associate, Miami, Florida, United States
🇺🇸
University of Pennslyvania, Philadelphia, Pennsylvania, United States
🇨🇦
CHU de Québec -Université Laval hopital CHUL Centre de Recherche en infectiologie, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy